M
Miklós Koppán
Researcher at University of Pécs
Publications - 66
Citations - 3310
Miklós Koppán is an academic researcher from University of Pécs. The author has contributed to research in topics: Receptor & Endometriosis. The author has an hindex of 22, co-authored 65 publications receiving 3187 citations. Previous affiliations of Miklós Koppán include Veterans Health Administration & Tulane University.
Papers
More filters
Journal ArticleDOI
Inflammation, atherosclerosis, and coronary artery disease.
Journal ArticleDOI
Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Attila Nagy,Andrew V. Schally,Andrew V. Schally,Gabor Halmos,Patricia Armatis,Renzhi Cai,Valer J. Csernus,Valer J. Csernus,Magdolna Kovacs,Magdolna Kovacs,Miklós Koppán,Miklós Koppán,Karoly Szepeshazi,Zsuzsanna Kahán +13 more
TL;DR: Preliminary studies in animal models of breast and prostate cancers showed that AN-238 is less toxic than AN-201 and more potent in inhibiting tumor growth and both compounds were found to suppress a stimulated growth hormone release at nanomolar concentrations.
Journal ArticleDOI
Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors
TL;DR: It is suggested that GH-RH antagonist MZ-5-156 may inhibit the growth of DU-145 human androgen-independent prostate cancers through a reduction in the production and mRNA expression of IGF-II by the tumor tissue.
Journal ArticleDOI
Endometriosis: harmful survival of an ectopic tissue
TL;DR: This review summarizes the current knowledge regarding the pathogenesis of endometriosis, including progress made with transgenic animals, and a clinical perspective on the diagnosis and management of this common process.
Journal Article
Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses
TL;DR: It is indicated that cytotoxic SST analogue AN-238 can be targeted to SSTRs on tumors and produces a powerful inhibition of the growth of Dunning-AT-1 rat prostate cancer at doses that are nontoxic, whereas its cytot toxic component, 2-pyrrolinodoxorubicin, is toxic and ineffective.